Cargando…

Yersinia V–Antigen Exploits Toll-like Receptor 2 and CD14 for Interleukin 10–mediated Immunosuppression

A characteristic of the three human-pathogenic Yersinia spp. (the plague agent Yersinia pestis and the enteropathogenic Yersinia pseudotuberculosis and Yersinia enterocolitica) is the expression of the virulence (V)-antigen (LcrV). LcrV is a released protein which is involved in contact-induced secr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sing, Andreas, Rost, Dagmar, Tvardovskaia, Natalia, Roggenkamp, Andreas, Wiedemann, Agnès, Kirschning, Carsten J., Aepfelbacher, Martin, Heesemann, Jürgen
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194041/
https://www.ncbi.nlm.nih.gov/pubmed/12391013
http://dx.doi.org/10.1084/jem.20020908
_version_ 1782147612265152512
author Sing, Andreas
Rost, Dagmar
Tvardovskaia, Natalia
Roggenkamp, Andreas
Wiedemann, Agnès
Kirschning, Carsten J.
Aepfelbacher, Martin
Heesemann, Jürgen
author_facet Sing, Andreas
Rost, Dagmar
Tvardovskaia, Natalia
Roggenkamp, Andreas
Wiedemann, Agnès
Kirschning, Carsten J.
Aepfelbacher, Martin
Heesemann, Jürgen
author_sort Sing, Andreas
collection PubMed
description A characteristic of the three human-pathogenic Yersinia spp. (the plague agent Yersinia pestis and the enteropathogenic Yersinia pseudotuberculosis and Yersinia enterocolitica) is the expression of the virulence (V)-antigen (LcrV). LcrV is a released protein which is involved in contact-induced secretion of yersinia antihost proteins and in evasion of the host's innate immune response. Here we report that recombinant LcrV signals in a CD14- and toll-like receptor 2 (TLR2)-dependent fashion leading to immunosuppression by interleukin 10 induction. The impact of this immunosuppressive effect for yersinia pathogenesis is underlined by the observation that TLR2-deficient mice are less susceptible to oral Y. enterocolitica infection than isogenic wild-type animals. In summary, these data demonstrate a new ligand specificity of TLR2, as LcrV is the first known secreted and nonlipidated virulence-associated protein of a Gram-negative bacterium using TLR2 for cell activation. We conclude that yersiniae might exploit host innate pattern recognition molecules and defense mechanisms to evade the host immune response.
format Text
id pubmed-2194041
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21940412008-04-11 Yersinia V–Antigen Exploits Toll-like Receptor 2 and CD14 for Interleukin 10–mediated Immunosuppression Sing, Andreas Rost, Dagmar Tvardovskaia, Natalia Roggenkamp, Andreas Wiedemann, Agnès Kirschning, Carsten J. Aepfelbacher, Martin Heesemann, Jürgen J Exp Med Article A characteristic of the three human-pathogenic Yersinia spp. (the plague agent Yersinia pestis and the enteropathogenic Yersinia pseudotuberculosis and Yersinia enterocolitica) is the expression of the virulence (V)-antigen (LcrV). LcrV is a released protein which is involved in contact-induced secretion of yersinia antihost proteins and in evasion of the host's innate immune response. Here we report that recombinant LcrV signals in a CD14- and toll-like receptor 2 (TLR2)-dependent fashion leading to immunosuppression by interleukin 10 induction. The impact of this immunosuppressive effect for yersinia pathogenesis is underlined by the observation that TLR2-deficient mice are less susceptible to oral Y. enterocolitica infection than isogenic wild-type animals. In summary, these data demonstrate a new ligand specificity of TLR2, as LcrV is the first known secreted and nonlipidated virulence-associated protein of a Gram-negative bacterium using TLR2 for cell activation. We conclude that yersiniae might exploit host innate pattern recognition molecules and defense mechanisms to evade the host immune response. The Rockefeller University Press 2002-10-21 /pmc/articles/PMC2194041/ /pubmed/12391013 http://dx.doi.org/10.1084/jem.20020908 Text en Copyright © 2002, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Article
Sing, Andreas
Rost, Dagmar
Tvardovskaia, Natalia
Roggenkamp, Andreas
Wiedemann, Agnès
Kirschning, Carsten J.
Aepfelbacher, Martin
Heesemann, Jürgen
Yersinia V–Antigen Exploits Toll-like Receptor 2 and CD14 for Interleukin 10–mediated Immunosuppression
title Yersinia V–Antigen Exploits Toll-like Receptor 2 and CD14 for Interleukin 10–mediated Immunosuppression
title_full Yersinia V–Antigen Exploits Toll-like Receptor 2 and CD14 for Interleukin 10–mediated Immunosuppression
title_fullStr Yersinia V–Antigen Exploits Toll-like Receptor 2 and CD14 for Interleukin 10–mediated Immunosuppression
title_full_unstemmed Yersinia V–Antigen Exploits Toll-like Receptor 2 and CD14 for Interleukin 10–mediated Immunosuppression
title_short Yersinia V–Antigen Exploits Toll-like Receptor 2 and CD14 for Interleukin 10–mediated Immunosuppression
title_sort yersinia v–antigen exploits toll-like receptor 2 and cd14 for interleukin 10–mediated immunosuppression
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194041/
https://www.ncbi.nlm.nih.gov/pubmed/12391013
http://dx.doi.org/10.1084/jem.20020908
work_keys_str_mv AT singandreas yersiniavantigenexploitstolllikereceptor2andcd14forinterleukin10mediatedimmunosuppression
AT rostdagmar yersiniavantigenexploitstolllikereceptor2andcd14forinterleukin10mediatedimmunosuppression
AT tvardovskaianatalia yersiniavantigenexploitstolllikereceptor2andcd14forinterleukin10mediatedimmunosuppression
AT roggenkampandreas yersiniavantigenexploitstolllikereceptor2andcd14forinterleukin10mediatedimmunosuppression
AT wiedemannagnes yersiniavantigenexploitstolllikereceptor2andcd14forinterleukin10mediatedimmunosuppression
AT kirschningcarstenj yersiniavantigenexploitstolllikereceptor2andcd14forinterleukin10mediatedimmunosuppression
AT aepfelbachermartin yersiniavantigenexploitstolllikereceptor2andcd14forinterleukin10mediatedimmunosuppression
AT heesemannjurgen yersiniavantigenexploitstolllikereceptor2andcd14forinterleukin10mediatedimmunosuppression